Physician profile
Lindsay Reck
NPI 1912453416
$17,612.53
in general payments reported to CMS, 2019-2025
31 companies · $3,958 in 2025
The $3,958 reported for 2025 was more than what 97% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,157 · 2022: $3,038 · 2023: $4,740 · 2024: $4,719 · 2025: $3,958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,794.50 |
| Education | $622.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,387.26 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Abbvie INC. | $3,306.08 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,226.63 | 2021-2025 | |
| Incyte Corporation | $982.60 | 2021-2025 | Opzelura |
| Dermavant Sciences, INC. | $784.10 | 2023-2024 | Vtama |
| Ucb, INC. | $741.73 | 2021-2025 | Bimzelx, Cimzia |
| Galderma Laboratories, L.P. | $696.64 | 2021-2025 | Nemluvio, Aklief |
| Sun Pharmaceutical Industries INC. | $695.68 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Pharmaceuticals, INC. | $658.67 | 2022-2025 | Dupixent |
| Genzyme Corporation | $643.28 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $620.12 | 2021-2025 | Dupixent, Libtayo |
| Pfizer INC. | $611.37 | 2022-2025 | |
| Amgen INC. | $584.21 | 2021-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $402.30 | 2023-2025 | Zoryve |
| Lilly USA, LLC | $346.68 | 2021-2025 | Taltz, Olumiant, Ebglyss |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $317.10 | 2022-2025 | Sotyktu |
| Leo Pharma INC. | $309.00 | 2021-2025 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $222.71 | 2021-2025 | Duobrii, Siliq, Cabtreo |
| Organon LLC | $199.19 | 2023-2025 | Vtama, Hadlima, Nexplanon |
| Epi Health, LLC | $184.13 | 2022 | |
| Almirall LLC | $121.86 | 2023 | Klisyri |
| Mayne Pharma Commercial LLC | $121.85 | 2022-2025 | |
| Fresenius Kabi USA, LLC | $117.00 | 2023-2025 | Idacio, Adalimumab-Aacf |
| Boehringer Ingelheim Pharmaceuticals, INC. | $78.94 | 2024-2025 | Spevigo |
| Janssen Scientific Affairs, LLC | $71.69 | 2022 | |
| Botanix Sb INC | $70.23 | 2025 | Sofdra |
| Journey Medical Corporation | $31.14 | 2023-2025 | |
| Mimedx Group, INC. | $24.81 | 2024 | |
| Elekta, INC. | $23.93 | 2025 | Flexitron Hdr |
| Verrica Pharmaceuticals INC. | $19.09 | 2024 | Ycanth |
| Vyne Pharmaceuticals INC. | $12.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Reck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.